Browse > Article
http://dx.doi.org/10.4162/nrp.2014.8.3.386

Protective effects of Acanthopanax divaricatus extract in mouse models of Alzheimer's disease  

Yan, Ji-Jing (Department of Pharmacology, College of Medicine, Hallym University)
Ahn, Won-Gyun (Department of Pharmacology, College of Medicine, Hallym University)
Jung, Jun-Sub (Department of Pharmacology, College of Medicine, Hallym University)
Kim, Hee-Sung (Department of Pharmacology, College of Medicine, Hallym University)
Hasan, Md. Ashraful (Department of Pharmacology, College of Medicine, Hallym University)
Song, Dong-Keun (Department of Pharmacology, College of Medicine, Hallym University)
Publication Information
Nutrition Research and Practice / v.8, no.4, 2014 , pp. 386-390 More about this Journal
Abstract
BACKGROUND: Acanthopanax divaricatus var. albeofructus (ADA) extract has been reported to have anti-oxidant, immunomodulatory, and anti-mutagenic activity. MATERIALS/METHODS: We investigated the effects of ADA extract on two mouse models of Alzheimer's disease (AD); intracerebroventricular injection of ${\beta}$-amyloid peptide ($A{\beta}$) and amyloid precursor protein/presenilin 1 (APP/PS1)-transgenic mice. RESULTS: Intra-gastric administration of ADA stem extract (0.25 g/kg, every 12 hrs started from one day prior to injection of $A{\beta}1$-42 until evaluation) effectively blocked $A{\beta}1$-42-induced impairment in passive avoidance performance, and $A{\beta}1$-42-induced increase in immunoreactivities of glial fibrillary acidic protein and interleukin (IL)-$1{\alpha}$ in the hippocampus. In addition, it alleviated the $A{\beta}1$-42-induced decrease in acetylcholine and increase in malondialdehyde levels in the cortex. In APP/PS1-transgenic mice, chronic oral administration of ADA stem extract (0.1 or 0.5 g/kg/day for six months from the age of six to 12 months) resulted in significantly enhanced performance of the novel-object recognition task, and reduced amyloid deposition and IL-$1{\beta}$ in the brain. CONCLUSIONS: The results of this study suggest that ADA stem extract may be useful for prevention and treatment of AD.
Keywords
Alzheimer disease; Acanthopanax divaricatus; ${\beta}$-amyloid peptide; amyloid precursor protein/presenilin 1;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012;148:1204-22.   DOI   ScienceOn
2 Maltsev AV, Bystryak S, Galzitskaya OV. The role of ${\beta}$-amyloid peptide in neurodegenerative diseases. Ageing Res Rev 2011;10: 440-52.   DOI   ScienceOn
3 Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010;6:108-19.   DOI   ScienceOn
4 Yan JJ, Cho JY, Kim HS, Kim KL, Jung JS, Huh SO, Suh HW, Kim YH, Song DK. Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br J Pharmacol 2001;133:89-96.   DOI   ScienceOn
5 Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001;21:8370-7.
6 Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D, Gordon MN. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 2002;22:2246-54.
7 Brekhman II, Dardymov IV. New substances of plant origin which increase nonspecific resistance. Annu Rev Pharmacol 1969;9:419-30.   DOI   ScienceOn
8 Yook CS. Medicinal Herbs of Acanthopanax in Asia. Seoul: Kyeongwon Media; 2001.
9 Kim JY, Yang KS. Screening of antioxidant activity of Acanthopanax species in vitro. Yakhak Hoeji 2003;47:361-4.
10 Lyu SY, Park WB. Th1/Th2 cytokine modulation in human PBMC by Acanthopanax divaricatus var. albeofructus. Food Sci Biotechnol 2008;17:631-6.
11 Hong CE, Cho MC, Jang HA, Lyu SY. Mutagenicity and anti- mutagenicity of Acanthopanax divaricatus var. albeofructus. J Toxicol Sci 2011;36:661-8.   DOI   ScienceOn
12 Laursen SE, Belknap JK. Intracerebroventricular injections in mice. Some methodological refinements. J Pharmacol Methods 1986;16:355-7.   DOI   ScienceOn
13 Sarter M, Bodewitz G, Stephens DN. Attenuation of scopolamine- induced impairment of spontaneous alteration behaviour by antagonist but not inverse agonist and agonist beta-carbolines. Psychopharmacology (Berl) 1988;94:491-5.   DOI
14 Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, Liu G, Tsien JZ. Genetic enhancement of learning and memory in mice. Nature 1999;401:63-9.   DOI   ScienceOn
15 Israël M, Lesbats B. Application to mammalian tissues of the chemiluminescent method for detecting acetylcholine. J Neurochem 1982;39:248-50.   DOI
16 Webber KM, Casadesus G, Perry G, Atwood CS, Bowen R, Smith MA. Gender differences in Alzheimer disease: the role of luteinizing hormone in disease pathogenesis. Alzheimer Dis Assoc Disord 2005;19:95-9.   DOI   ScienceOn
17 Baker H, Farbman AI. Olfactory afferent regulation of the dopamine phenotype in the fetal rat olfactory system. Neuroscience 1993;52: 115-34.   DOI   ScienceOn
18 Cho JY, Kim HS, Kim DH, Yan JJ, Suh HW, Song DK. Inhibitory effects of long-term administration of ferulic acid on astrocyte activation induced by intracerebroventricular injection of beta-amyloid peptide (1-42) in mice. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:901-7.   DOI   ScienceOn
19 Fu AL, Dong ZH, Sun MJ. Protective effect of N-acetyl-L-cysteine on amyloid beta-peptide-induced learning and memory deficits in mice. Brain Res 2006;1109:201-6.   DOI   ScienceOn
20 Kim HS, Cho JY, Kim DH, Yan JJ, Lee HK, Suh HW, Song DK. Inhibitory effects of long-term administration of ferulic acid on microglial activation induced by intracerebroventricular injection of beta- amyloid peptide (1-42) in mice. Biol Pharm Bull 2004;27:120-1.   DOI   ScienceOn
21 Dumont M, Beal MF. Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic Biol Med 2011;51:1014-26.   DOI   ScienceOn